Mogling Bio

Mogling Bio

Mogling Bio At mogling bio, we are pioneering pharmacological solutions to restore the function of aged and exhausted cells—particularly stem cells—addressing a root cause of tissue degeneration and age related diseases. Information on valuation, funding, cap tables, investors, and executives for mogling bio. use the pitchbook platform to explore the full profile.

Mogling Bio

Mogling Bio With operations in both the us and germany, mogling is developing small molecules designed to rejuvenate old stem cells of the blood cell formation system, known as hematopoietic stem cells (hscs). Mogling bio, a german biotech startup, announced it has successfully completed its first seed investment round from sole investor venture capital firm kizoo technology capital, a rejuvenation biotech investor focused on startups reversing age related damage on a cellular and molecular level. Mogling bio is a company that uses novel pharmacological approaches to rejuvenate old stem cells. Mogling bio is developing new pharmacological approaches to rejuvenate old stem cells of the hematopoietic (blood cell formation) system.

Mogling Bio

Mogling Bio Mogling bio is a company that uses novel pharmacological approaches to rejuvenate old stem cells. Mogling bio is developing new pharmacological approaches to rejuvenate old stem cells of the hematopoietic (blood cell formation) system. Mogling bio inc., a privately owned, preclinical stage biopharmaceutical company, entered into a global exclusive agreement with cincinnati children’s for continued development of cdc42 inhibitors to rejuvenate aged hscs. Mogling bio is a biotechnology company focused on developing pharmacological approaches to rejuvenate old stem cells. use the cb insights platform to explore mogling bio's full profile. Mogling bio inc. is developing new pharmacological approaches to rejuvenate old stem cells of the hematopoietic (blood cell formation) system. aging causes stem cells to lose their normal structure by increased activity of the protein cdc42. Mogling bio inc. is developing new pharmacological approaches to rejuvenate old stem cells of the hematopoietic (blood cell formation) system. aging causes stem cells to lose their normal structure by increased activity of the protein cdc42.

Longevity Investors Conference 2024 | Startup Innovation Showcase - Mogling Bio